Status:
COMPLETED
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
Lead Sponsor:
Allergan
Conditions:
Anti-biotic Resistance
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface f...
Eligibility Criteria
Inclusion
- Male or Female
- At least 50 years of age
- In good general health
Exclusion
- Any ocular surgery or use of topical antibiotics or antiseptics in either eye within the last 3 months
- Use of topical steroids, or non-steroidal anti inflammatory drugs in either eye within 30 days of Baseline (or anticipated during the study)
- Use of lid scrubs within 7 days of Baseline in either eye (or anticipated use during the study)
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00874887
Start Date
March 1 2009
End Date
October 1 2009
Last Update
December 19 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Minneapolis, Minnesota, United States
2
Saskatoon, Saskatchewan, Canada